Cargando…
Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review
Sexual dysfunction is an underdiscussed adverse effect to selective serotonin reuptake inhibitors (SSRIs) and may increase the risk for discontinuation and nonadherence to antidepressant pharmacotherapy. Given the prevalence of depression, health care providers should educate patients about SSRI-ass...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
College of Psychiatric & Neurologic Pharmacists
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007725/ https://www.ncbi.nlm.nih.gov/pubmed/29955469 http://dx.doi.org/10.9740/mhc.2016.07.191 |
_version_ | 1783333084177891328 |
---|---|
author | Jing, Elizabeth Straw-Wilson, Kristyn |
author_facet | Jing, Elizabeth Straw-Wilson, Kristyn |
author_sort | Jing, Elizabeth |
collection | PubMed |
description | Sexual dysfunction is an underdiscussed adverse effect to selective serotonin reuptake inhibitors (SSRIs) and may increase the risk for discontinuation and nonadherence to antidepressant pharmacotherapy. Given the prevalence of depression, health care providers should educate patients about SSRI-associated sexual dysfunction in order to promote patient awareness and medication adherence. This study evaluated primary literature from 1997 to 2015 to identify SSRI-related sexual side effects, therapeutic alternatives, and treatment strategies. The results indicate that paroxetine is associated with the greatest rate of sexual dysfunction among the SSRIs. Potential alternatives to SSRI treatment include bupropion, mirtazapine, vilazodone, vortioxetine, and serotonin-norepinephrine reuptake inhibitors. In the event that a subject responds solely to SSRIs but experiences unwanted sexual side effects, bupropion may be added as an adjunctive medication. Some limited evidence also suggests that saffron may reduce some aspects of sexual dysfunction, excluding ability to reach orgasm. |
format | Online Article Text |
id | pubmed-6007725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | College of Psychiatric & Neurologic Pharmacists |
record_format | MEDLINE/PubMed |
spelling | pubmed-60077252018-06-28 Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review Jing, Elizabeth Straw-Wilson, Kristyn Ment Health Clin Physical Side Effects of Psychoactive Meds Sexual dysfunction is an underdiscussed adverse effect to selective serotonin reuptake inhibitors (SSRIs) and may increase the risk for discontinuation and nonadherence to antidepressant pharmacotherapy. Given the prevalence of depression, health care providers should educate patients about SSRI-associated sexual dysfunction in order to promote patient awareness and medication adherence. This study evaluated primary literature from 1997 to 2015 to identify SSRI-related sexual side effects, therapeutic alternatives, and treatment strategies. The results indicate that paroxetine is associated with the greatest rate of sexual dysfunction among the SSRIs. Potential alternatives to SSRI treatment include bupropion, mirtazapine, vilazodone, vortioxetine, and serotonin-norepinephrine reuptake inhibitors. In the event that a subject responds solely to SSRIs but experiences unwanted sexual side effects, bupropion may be added as an adjunctive medication. Some limited evidence also suggests that saffron may reduce some aspects of sexual dysfunction, excluding ability to reach orgasm. College of Psychiatric & Neurologic Pharmacists 2016-06-29 /pmc/articles/PMC6007725/ /pubmed/29955469 http://dx.doi.org/10.9740/mhc.2016.07.191 Text en © 2016 CPNP. http://creativecommons.org/licenses/by-nc/3.0/ The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Physical Side Effects of Psychoactive Meds Jing, Elizabeth Straw-Wilson, Kristyn Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review |
title | Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review |
title_full | Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review |
title_fullStr | Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review |
title_full_unstemmed | Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review |
title_short | Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review |
title_sort | sexual dysfunction in selective serotonin reuptake inhibitors (ssris) and potential solutions: a narrative literature review |
topic | Physical Side Effects of Psychoactive Meds |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007725/ https://www.ncbi.nlm.nih.gov/pubmed/29955469 http://dx.doi.org/10.9740/mhc.2016.07.191 |
work_keys_str_mv | AT jingelizabeth sexualdysfunctioninselectiveserotoninreuptakeinhibitorsssrisandpotentialsolutionsanarrativeliteraturereview AT strawwilsonkristyn sexualdysfunctioninselectiveserotoninreuptakeinhibitorsssrisandpotentialsolutionsanarrativeliteraturereview |